CTNM

8.6803.98%
TR

Todd R. Brady

Independent Director

Mr. Todd R. Brady served as Independent Director at Avidity Biosciences Inc. since December 2016 until January 11, 2021. He serves as a Director of Contineum Therapeutics, Inc. (formerly known as Pipeline Therapeutics, Inc.) since November 2019. He was Director at Antiva Biosciences, Inc. since January 2023 until 2023. Mr. Brady was Director of Cocrystal Pharma, Inc. since February 1, 2019 until March 10, 2020. Mr. Brady serves as a Director of Finance and was Director Investments at Brace Pharma Capital since April 2014. Mr. Brady has an extensive and diverse background in Capital Markets, working in equity research, asset management, private equity and corporate banking over the duration of his career. He serves as a Director of GeNO LLC, Avidity Biosciences LLC and Tyrogenex, Inc. He serves as Board Observer for Avidity Nanomedicines and Miragen Therapeutics. He also serves as a Director for Vero Biotech, LLC and formerly served as board observer for Precision Biosciences Inc. He currently serves as the Chief Executive Officer of Vero Biotech Inc. since September 2025. He holds an Masters of Business Administration from the Schulich School of Business (York University) in 2007 and is a Chartered Financial Analyst (CFA).

Positions